Ibex Wealth Advisors Acquires 14,837 Shares of Amgen Inc. $AMGN

Ibex Wealth Advisors boosted its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 51.3% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 43,734 shares of the medical research company’s stock after purchasing an additional 14,837 shares during the period. Amgen comprises about 1.4% of Ibex Wealth Advisors’ investment portfolio, making the stock its 20th biggest position. Ibex Wealth Advisors’ holdings in Amgen were worth $15,388,000 as of its most recent filing with the SEC.

Several other hedge funds have also bought and sold shares of AMGN. Norges Bank purchased a new stake in Amgen in the 4th quarter worth approximately $2,164,162,000. Capital World Investors boosted its position in shares of Amgen by 22.9% in the fourth quarter. Capital World Investors now owns 23,097,711 shares of the medical research company’s stock worth $7,560,249,000 after purchasing an additional 4,302,237 shares during the period. State Street Corp increased its stake in shares of Amgen by 4.4% in the fourth quarter. State Street Corp now owns 30,591,403 shares of the medical research company’s stock worth $10,012,872,000 after purchasing an additional 1,287,310 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Amgen by 7.8% in the fourth quarter. Geode Capital Management LLC now owns 14,303,294 shares of the medical research company’s stock worth $4,665,822,000 after purchasing an additional 1,035,779 shares in the last quarter. Finally, Amundi raised its position in shares of Amgen by 41.1% during the 4th quarter. Amundi now owns 3,396,945 shares of the medical research company’s stock valued at $1,111,854,000 after purchasing an additional 988,856 shares during the period. Institutional investors own 76.50% of the company’s stock.

Amgen Price Performance

AMGN stock opened at $363.62 on Friday. The stock has a market cap of $196.25 billion, a PE ratio of 25.30, a P/E/G ratio of 3.63 and a beta of 0.41. Amgen Inc. has a 12 month low of $269.77 and a 12 month high of $391.29. The company has a 50-day moving average price of $344.30 and a 200 day moving average price of $349.22. The company has a current ratio of 1.26, a quick ratio of 1.01 and a debt-to-equity ratio of 5.65.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.77 by $0.38. The company had revenue of $8.62 billion during the quarter, compared to analysts’ expectations of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.Amgen’s revenue was up 5.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Equities research analysts anticipate that Amgen Inc. will post 22.32 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. Truist Financial boosted their price objective on Amgen from $327.00 to $340.00 and gave the company a “hold” rating in a research report on Tuesday. UBS Group lifted their target price on Amgen from $390.00 to $400.00 and gave the company a “buy” rating in a research note on Monday, April 13th. BMO Capital Markets restated an “outperform” rating and issued a $400.00 price target on shares of Amgen in a research note on Wednesday, July 1st. The Goldman Sachs Group set a $389.00 price objective on shares of Amgen in a research report on Friday, June 5th. Finally, Wells Fargo & Company boosted their target price on shares of Amgen from $375.00 to $390.00 and gave the stock an “equal weight” rating in a report on Thursday, March 19th. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, fifteen have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $355.73.

Insider Buying and Selling

In related news, SVP Nancy A. Grygiel sold 1,237 shares of Amgen stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $323.73, for a total transaction of $400,454.01. Following the transaction, the senior vice president directly owned 7,009 shares of the company’s stock, valued at $2,269,023.57. This trade represents a 15.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Company insiders own 0.85% of the company’s stock.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.